Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BPTSY
Biophytis
$1.45
$1.75
$1.38
$7.48
$509K0.811,922 shs20 shs
LCIN
Lannett
$0.02
$0.01
$0.02
$160K0.92475,780 shs441,200 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.04
-15.1%
$0.05
$0.04
$17.00
$199K1.72438,985 shs20,532 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.39
-2.8%
$0.27
$0.13
$84.75
$483K1.58202,574 shs31,581 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BPTSY
Biophytis
0.00%+5.07%-16.18%-56.85%-79.69%
LCIN
Lannett
0.00%0.00%0.00%0.00%0.00%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%-23.80%-36.39%-93.70%-99.75%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+23.49%+61.95%+11.14%-97.07%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BPTSY
Biophytis
N/AN/AN/AN/AN/AN/AN/AN/A
LCIN
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
2.4685 of 5 stars
3.53.00.00.00.01.71.3
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
1.3565 of 5 stars
3.03.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BPTSY
Biophytis
0.00
N/AN/AN/A
LCIN
Lannett
0.00
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
3.00
Buy$40.00104,886.88% Upside
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
2.00
Hold$75.0019,180.21% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BPTSY
Biophytis
N/AN/AN/AN/A($16.18) per shareN/A
LCIN
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$1.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BPTSY
Biophytis
-$18.43MN/A0.00N/AN/AN/AN/AN/A
LCIN
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%8/6/2025 (Estimated)
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
-$15.19MN/A0.00N/AN/A-1,554.34%-338.29%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BPTSY
Biophytis
N/AN/AN/AN/AN/A
LCIN
Lannett
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BPTSY
Biophytis
N/A
0.41
N/A
LCIN
Lannett
N/A
2.23
1.39
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
BPTSY
Biophytis
0.05%
LCIN
Lannett
40.28%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
32.23%

Insider Ownership

CompanyInsider Ownership
BPTSY
Biophytis
3.70%
LCIN
Lannett
13.12%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
BPTSY
Biophytis
30351,000338,000N/A
LCIN
Lannett
N/A10.49 million9.35 millionOptionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
71.24 million4.71 millionNot Optionable

Recent News About These Companies

Virpax Pharmaceuticals Inc trading halted, news pending
Virpax receives positive Probudur results for dose range study
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biophytis NASDAQ:BPTSY

$1.45 0.00 (0.00%)
As of 07/3/2025

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Lannett NYSE:LCIN

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.04 -0.01 (-15.14%)
As of 07/3/2025 12:54 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Virpax Pharmaceuticals stock logo

Virpax Pharmaceuticals NASDAQ:VRPX

$0.39 -0.01 (-2.77%)
As of 07/3/2025 12:28 PM Eastern

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.